Date Filed | Type | Description |
10/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/10/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
10/05/2023 |
4/A
| Bernards Rene (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Bought 4,473 shares
@ $2.29, valued at
$10.2k
Bought 5,527 shares
@ $2.51, valued at
$13.9k
|
|
10/05/2023 |
4
| van der Baan Bastiaan Jeroen (President and CEO) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Bought 10,000 shares
@ $2.8, valued at
$28k
|
|
10/04/2023 |
4
| Bernards Rene (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Bought 4,473 shares
@ $2.29, valued at
$10.2k
Bought 5,527 shares
@ $2.51, valued at
$13.9k
|
|
09/29/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
09/27/2023 |
8-K
| Quarterly results |
09/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/22/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/01/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
07/21/2023 |
8-K
| Quarterly results |
07/20/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
07/20/2023 |
8-K
| Quarterly results |
07/07/2023 |
4
| van der Baan Bastiaan Jeroen (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Granted 10,000 options to buy
@ $5.88, valued at
$58.8k
Granted 25,000 options to buy
@ $7.4, valued at
$185k
|
|
07/07/2023 |
4
| Yen Yun (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Granted 10,000 options to buy
@ $5.88, valued at
$58.8k
|
|
07/07/2023 |
4
| Brown Regina (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Granted 10,000 options to buy
@ $5.88, valued at
$58.8k
|
|
07/07/2023 |
4
| Forman Stephen J. (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Txns:
| Granted 10,000 options to buy
@ $5.88, valued at
$58.8k
|
|
05/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/25/2023 |
8-K
| Quarterly results |
04/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
01/05/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/23/2022 |
8-K
| Quarterly results |
12/16/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/06/2022 |
8-K
| Quarterly results |
12/02/2022 |
8-K
| Quarterly results |
|